Wells Fargo Maintains Overweight on Amrize, Lowers Price Target to $58

Benzinga Newsdesk www.benzinga.com Negative 86.1%

Neg 86.1% Neu 0% Pos 0%

Wells Fargo analyst Timna Tanners maintains Amrize (NYSE:AMRZ) with a Overweight and lowers the price target from $65 to $58.